How many drugs treat Metastatic malignant melanoma?

Drug Landscape tracks 10 marketed treatments for Metastatic malignant melanoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-malignant-melanoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic malignant melanoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic malignant melanoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic malignant melanoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Braftovi	encorafenib	Pfizer		RAF proto-oncogene serine/threonine-protein kinase	2018-01-01
Mektovi	mek162	Pfizer		Dual specificity mitogen-activated protein kinase kinase 1	2018-01-01
Cotellic	cobimetinib	Roche	Kinase Inhibitor	Dual specificity mitogen-activated protein kinase kinase 1	2015-01-01
Opdivo	nivolumab	Bristol-Myers Squibb	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death protein 1	2014-01-01
Mekinist	trametinib	Novartis	Kinase Inhibitor	Dual specificity mitogen-activated protein kinase kinase 2	2013-01-01
Tafinlar	dabrafenib	Novartis	Kinase Inhibitor	Serine/threonine-protein kinase B-raf	2013-01-01
Proleukin	ALDESLEUKIN	Chiron	Lymphocyte Growth Factor [EPC]	Interleukin-2 receptor	1992-01-01
Dtic-Dome	dacarbazine	Bayer	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1975-01-01
Yervoy	Yervoy	Bristol-Myers Squibb		Cytotoxic T-lymphocyte protein 4
Pembrolizuma	Pembrolizuma	Memorial Sloan Kettering Cancer Center		Programmed cell death protein 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Metastatic malignant melanoma
Bristol-Myers Squibb · 3 drugs in Metastatic malignant melanoma
Novartis · 2 drugs in Metastatic malignant melanoma
Roche · 1 drug in Metastatic malignant melanoma
Bayer · 1 drug in Metastatic malignant melanoma
University of Minnesota · 1 drug in Metastatic malignant melanoma
Chiron · 1 drug in Metastatic malignant melanoma
Memorial Sloan Kettering Cancer Center · 1 drug in Metastatic malignant melanoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic malignant melanoma:

Cite this brief

Drug Landscape (2026). Metastatic malignant melanoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-malignant-melanoma. Accessed 2026-06-10.

Metastatic malignant melanoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing